Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer
| Autor: | Tohru Ohmori, Kentaro Okuda, Takao Shirai, Tomohide Sugiyama, Toshimitsu Yamaoka, Sojiro Kusumoto, Takashi Hirose, Mitsuru Adachi, Yasunori Murata, Masanao Nakashima |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Lung Neoplasms Time Factors medicine.medical_treatment Phases of clinical research Neutropenia Irinotecan Medical Oncology Gastroenterology Disease-Free Survival Carboplatin chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Progression-free survival Lung cancer Aged Aged 80 and over Chemotherapy Performance status business.industry medicine.disease Small Cell Lung Carcinoma Surgery Treatment Outcome Oncology chemistry Camptothecin Female Safety business medicine.drug |
| Zdroj: | European Journal of Cancer. 47:1336-1342 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/j.ejca.2011.03.007 |
| Popis: | Aim The aim of the present phase II study was to assess the antitumour activity and safety of the combination of irinotecan and carboplatin in elderly patients with small-cell lung cancer (SCLC). Material and methods Patients with previously untreated SCLC were eligible if they had a performance status of 0–2, were 70 years or older, and had adequate organ function. Patients were treated with carboplatin at an area under the plasma concentration versus time curve of 5 min/ml on day 1 and with irinotecan at 50 mg/m2 on days 1 and 8 every 3 weeks. Results Thirty patients (26 men and 4 women; median age, 76 years; age range, 70–86 years) were enrolled. Eight patients had limited disease (LD) and 22 patients had extensive disease (ED). The overall response rate was 83.3% (95% confidence interval: 65.3–94.4%). Response rates did not differ significantly between patients with LD (87.5%) and those with ED (81.8%; p = 0.71). The median survival time was 14 months overall and was significantly longer in patients with LD (26 months) than in patients with ED (11 months; p = 0.025). The median progression free survival time was 6 months overall and was significantly longer in patients with LD (12 months) than in patients with ED (6 months; p = 0.016). Grade 3–4 toxicities included neutropenia in 83% of patients, thrombocytopenia in 47%, anaemia in 60%, infection in 23%, and diarrhoea in 20%. There were no treatment-related deaths. Conclusions This chemotherapy is safe and effective for elderly patients with SCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect